Byline: Market Analysis & Forecast Amneal Pharmaceuticals is starting to look very different from the struggling generics company investors once ignored. Recent CEO commentary and strategic moves point to a clear shift: 👉 diversification, margin expansion, and a push into higher-value biosimilars And the latest developments—especially the Kashiv BioSciences acquisition—reinforce that this is no longer just a low-margin generics story. The News: A Strategic Upgrade to Growth The biggest recent catalyst: $1.1B acquisition of Kashiv BioSciences Goal: build a fully integrated global biosimilars platform This is critical because: 👉 Over $300B in biologic drugs are losing patent protection over the next decade That’s the opportunity Amneal is targeting. The Numbers: Quiet but Real Progress 2025 Performance Revenue: $3.02B (+8%) Net Income: $72M (vs loss prior year) EBITDA: $688M (+10%) 2026 Outlook Revenue: $3.1B–$3.2B EPS: $0.93–$1.05 E...